Kroger Shares Outperform Market Amid Earnings Momentum but Rank 339th in Daily Trading Volume Amid FDA Scrutiny

Market Snapshot

On January 23, 2026, The Kroger Co. , outperforming the broader market. The stock traded with a volume of $0.37 billion, ranking 339th in total trading activity for the day. Over the past 52 weeks, , .

Key Drivers

Kroger’s recent performance reflects a mix of earnings momentum and regulatory headwinds. Analysts anticipate strong fiscal 2025 results, , . The company has exceeded Wall Street’s bottom-line estimates in four consecutive quarters, , . For fiscal 2026, projections suggest further growth, . This consistent earnings outperformance has bolstered investor confidence, supported by a “Moderate Buy” rating from 22 analysts, .

However, recent volatility highlights operational challenges. On December 4, . , , . The underperformance in revenue, despite earnings gains, raised concerns about pricing pressures and demand dynamics in the retail sector. This duality—strong profitability but weaker top-line growth—has created a tug-of-war for investor sentiment.

Regulatory scrutiny also looms. Kroger received a warning letter from the FDA in January 2026 for continuing to sell infant formula linked to a outbreak, despite a recall by supplier . While the FDA did not identify the contaminated ingredient or its source, the incident underscores risks associated with third-party suppliers in the food retail chain. The company’s reputation and compliance practices are under heightened scrutiny, which could weigh on future operations.

. Unlike the S&P 500’s broader rally, Kroger’s gains have been tempered by its cyclical exposure to consumer staples. Yet, its slight outperformance relative to the XLP ETF suggests it has retained appeal among investors prioritizing defensive sectors. Analysts attribute this to Kroger’s diversified store formats, including drug retail and discount warehouses, which provide a buffer against macroeconomic volatility.

Looking ahead, the upcoming Q4 2025 earnings report will be critical. If Kroger continues to beat estimates, the stock could see renewed momentum. Conversely, any deviation from expectations—particularly in revenue—may reignite investor caution. The FDA’s ongoing oversight of infant formula recalls also remains a wildcard, as regulatory actions could disrupt supply chains or erode consumer trust.

In summary, Kroger’s stock is navigating a landscape of earnings optimism and operational risks. While its consistent profitability and strategic diversification have attracted a “Moderate Buy” consensus, near-term performance will hinge on its ability to address supply chain vulnerabilities and maintain revenue growth.